VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2016 | Global differences in cancer drug prices: a comparative analysis

Daniel Goldstein • 3 Jun 2016
ASCO 2016
Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecological Cancer Lung Cancer Skin Cancer

Press brief by Daniel Goldstein, MD of the Rabin Medical Center, Petah Tikva, Israel, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

More from Daniel Goldstein

2:15
Personalized dosing of pembrolizumab has the potential to save $0.8 billion per year
Daniel Goldstein
0:51
Are physicians wasting healthcare resources by over-prescribing drugs?
Daniel Goldstein • 2 Jun 2017
2:09
Is the current dose of pembrolizumab approved for treating lung cancer too high?
Daniel Goldstein • 2 Jun 2017
0:52
Cancer care: the need for a cost-effective approach
Daniel Goldstein • 2 Jun 2017

Related Videos

1:19
Targeted therapies for patients with HER2+ colorectal cancer
John Strickler • 1 Jul 2022
0:46
MOUNTAINEER-03: tucatinib plus trastuzumab plus FOLFOX for first-line treatment of mCRC
John Strickler • 1 Jul 2022
2:28
MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer
John Strickler • 1 Jul 2022
0:56
Highlights from ESMO WCGIC 2022
John Strickler • 1 Jul 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals